Frontiers in Medicine
Recurrence of generalized cutaneous lichen planus after switching from PD-1 to PD-L1 in a patient with pre-existing oral lichen planus: a case report
We present a clinicopathologically documented case of generalized cutaneous lichen planus that recurred after switching from a programmed death 1 (PD-1) inhibitor (camrelizumab) to its ligand PD-L1 inhibitor (atezolizumab) in a patient with pre-existing oral lichen planus. While relapse of induce immune-related adverse events (irAEs) after PD-1/PD-L1 switching has been previously reported, most of these reports described cutaneous manifestations merely as “rash” without detailed dermatological characterization. In …